The Onchocerciasis Vaccine for Africa—TOVA—Initiative

PLoS Neglected Tropical Diseases

Volumn 9, Issue 1, 2015, Pages

  Hotez, Peter J ^a   Bottazzi, Maria Elena ^a   Zhan, Bin ^a   Makepeace, Benjamin L ^b   Klei, Thomas R ^c   Abraham, David ^d   Taylor, David W ^e   Lustigman, Sara ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; MOXIDECTIN; ONCHOCERCIASIS VACCINE; UNCLASSIFIED DRUG; VACCINE;

AFRICA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH PROGRAM; HUMAN; IMMUNITY; NONHUMAN; ONCHOCERCIASIS; PARASITE CLEARANCE; PARASITE CONTROL; VECTOR CONTROL; WORLD HEALTH ORGANIZATION;

EID: 84922249638     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003422     Document Type: Editorial

References (19)

1. World Bank (2014) World Bank Live, River Blindness: 40th Anniversary Summit. http://live.worldbank.org/river-blindness. Accessed 21 Jun 2014.
2. World Health Organization (2014) Media Centre, Onchocerciasis. http://www.who.int/mediacentre/factsheets/fs374/en/. Accessed 21 June 2014.
3. Coffeng LE, Stolk WA, Zoure HG, Veerman JL, Agblewonu KB, et al. (2013) African Programme For Onchocerciasis Control 1995–2015: model-estimated health impact and cost. PLoS Negl Trop Dis 7: e2032. doi: 10.1371/journal.pntd.0002032 23383355
4. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, et al. (2012) Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 6: e1825. doi: 10.1371/journal.pntd.0001825 23029586
5. World Health Organization (2012) World Health Organization’s 2020 Roadmap on NTDs. http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf. Accessed June 21, 2014.
6. Kelly-Hope LA, Cano J, Stanton MC, Bockarie MJ, Molyneux DH, (2014) Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. Parasites & vectors 7: 307. doi: 10.1111/mmi.12922 25566405
7. Farrar J HP, Junghanss T, Kang G, Lalloo D, eds. (2014) Manson’s Tropical Diseases. 23rd ed. Edinburgh: Saunders Elsevier. 25566584
8. Lustigman S, McCarter JP, (2007) Ivermectin resistance in Onchocerca volvulus: toward a genetic basis. PLoS Negl Trop Dis 1: e76. 17989789
9. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, et al. (2013) Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. PLoS Negl Trop Dis 7: e2169. doi: 10.1371/journal.pntd.0002169 23634234
10. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, et al. (2014) Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Clin Infect Dis 59: 923–932. doi: 10.1093/cid/ciu467 24944228
11. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC, (2014) A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis 8: e2953 doi: 10.1371/journal.pntd.0002953 24968000
12. Geary TG, Mackenzie CD, (2011) Progress and challenges in the discovery of macrofilaricidal drugs. Expert review of anti-infective therapy 9: 681–695. doi: 10.1586/eri.11.76 21819332
13. Prichard RK, Basanez MG, Boatin BA, McCarthy JS, Garcia HH, et al. (2012) A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis 6: e1549. doi: 10.1371/journal.pntd.0001549 22545163
14. Makepeace BL, Jensen SA, Laney SJ, Nfon CK, Njongmeta LM, et al. (2009) Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Negl Trop Dis 3: e544. doi: 10.1371/journal.pntd.0000544 19901988
15. Hess JA, Zhan B, Bonne-Annee S, Deckman JM, Bottazzi ME, et al. (2014) Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol 44: 637–646. doi: 10.1016/j.ijpara.2014.04.006 24907553
16. Arumugam S, Wei J, Ward D, Abraham D, Lustigman S, et al. (2014) Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. Int J Parasitol 44:675–579. doi: 10.1016/j.ijpara.2014.05.003 24929131
17. Babayan SA, Luo H, Gray N, Taylor DW, Allen JE, (2012) Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes. PLoS Negl Trop Dis 6: e1968. doi: 10.1371/journal.pntd.0001968 23301106
18. Lustigman S MJ, Bottazzi ME, Caffrey CR, (2012) Vaccines Linked to Chemotherapy: A New Approach to Control Helminth Infections. In: Parasitic Helminths: Targets, Screens, Drugs and Vaccines. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA.
19. World Health Organization (2014) African Programme for Onchocerciasis Control (APOC), Technical Consultative Committee (TCC). http://www.who.int/apoc/about/structure/tcc/en/. Accessed 28 Jun 2014.